Difference between revisions of "MT-LIPCAR"
| (One intermediate revision by the same user not shown) | |||
| Line 10: | Line 10: | ||
===Chromosome=== | ===Chromosome=== | ||
mitochondria | mitochondria | ||
| − | === | + | ===Disease=== |
| − | + | heart failure | |
| − | |||
| − | |||
===pubmed IDs=== | ===pubmed IDs=== | ||
24663402 | 24663402 | ||
| Line 24: | Line 22: | ||
===Function=== | ===Function=== | ||
| − | LIPCAR is a novel biomarker of cardiac remodeling and predicts future death in patients with heart failure. | + | LIPCAR is a novel biomarker of cardiac remodeling and predicts future death in patients with heart failure.<ref name="ref1" /> |
===Regulation=== | ===Regulation=== | ||
| Line 33: | Line 31: | ||
===Expression=== | ===Expression=== | ||
| − | LIPCAR are downregulated at baseline, but significantly upregulated later on during the development of HF. | + | LIPCAR are downregulated at baseline, but significantly upregulated later on during the development of HF.<ref name="ref1" /> |
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
Latest revision as of 12:30, 1 July 2016
Contents
Annotated Information
Approved Symbol
MT-LIPCAR
Approved Name
mitochondrially encoded long non-coding cardiac associated RNA
Previous Symbols
Synonyms
uc022bqs.1, LIPCAR
Chromosome
mitochondria
Disease
heart failure
pubmed IDs
24663402
Characteristics
LIPCAR, a long intergenic noncoding RNA predicting cardiac remodeling and survival of patients with HF.[1].
Cellular Localization
A mitochondrial long noncoding RNA.[1].
Function
LIPCAR is a novel biomarker of cardiac remodeling and predicts future death in patients with heart failure.[1]
Regulation
The mitochondrial long noncoding RNA uc022bqs.1 (LIPCAR) was downregulated early after myocardial infarction but upregulated during later stages.[1].
Diseases
- heart failure
Expression
LIPCAR are downregulated at baseline, but significantly upregulated later on during the development of HF.[1]
Labs working on this lncRNA
- From the Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx (R.K., I.V., J.F., A.H., T.T.) and REBIRTH Excellence Cluster (T.T.), Hannover Medical School, Hannover, Germany; Inserm, U744, University Lille Nord de France, Lille, France (C.B., F.M., G.L., P.d.G., F.P.); Institut Pasteur de Lille, Lille, France (C.B., F.M., G.L., P.d.G., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (C.B., G.L., P.d.G., F.P.); Faculté de Médecine de Lille, Lille, France (C.B., G.L.); and National Heart and Lung Institute, Imperial College London, London, United Kingdom (T.T.). [1].
